Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF43.75
CHF0.05(0.11%)
At close: 4:00 PM EDT
CHF43.75
CHF0.05(0.11%)
Day’s Range― - ―
52-Week RangeCHF21.15 - CHF50.10
Previous CloseN/A
Volume526.45K
Average Volume (3M)34.07K
Market Cap
CHF1.45B
Enterprise ValueCHF913.55
Total Cash (Recent Filing)CHF74.53M
Total Debt (Recent Filing)CHF130.46M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 13, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF40.67Price Target Upside-7.05% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)CHF490.06M
Bulls Say, Bears Say
Bulls Say
End-to-end CDMO ModelA full-lifecycle CDMO model creates durable demand by capturing fees at development and commercial stages. Serving discovery-to-commercial customers builds long-term relationships, recurring commercial-supply contracts and higher switching costs, supporting revenue visibility and client retention over multiple years.
Consistent Revenue GrowthSustained top-line growth indicates ongoing demand for peptide APIs and successful project wins. Steady revenue expansion supports scale economies, capacity utilization improvements and the potential to restore margins as commercial volumes increase, benefiting medium-term earnings resilience.
Operating Cash Flow ImprovementImproved operating cash flow demonstrates core business cash generation despite accounting losses. Reliable operational cash allows internal funding for process development and capacity investment, reducing near-term reliance on external capital and supporting sustainable commercial scaling.
Bears Say
Persistent Net LossesRepeated net losses over multiple years erode retained equity and limit reinvestment capacity. Ongoing negative profitability constrains the firm’s ability to self-fund expansion, may force dilutive financing or higher leverage, and delays the conversion of revenue growth into shareholder returns.
Free Cash Flow VolatilityHighly variable free cash flow reduces predictability for capital allocation and strategic investments. Sharp negative FCF in 2025 signals heavy capex or working-capital strain, increasing the risk of external funding needs and making long-term capacity planning and margin recovery more uncertain.
Rising Leverage And Weaker EquityAn upward trend in leverage coupled with declining equity reduces financial flexibility. Higher debt levels increase fixed costs and constrain capacity to absorb setbacks, making the company more sensitive to cash-flow swings and potentially limiting strategic investments during industry cycles.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF21.15 and its highest was CHF50.10 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.45B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Mar 12, 2026. The company reported CHF0.152 earnings per share for the quarter, missing the consensus estimate of CHF0.271 by -CHF0.119.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Overvalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.07.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.152 in its last earnings report, missing expectations of CHF0.271. Following the earnings report the stock price went up 8.776%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF40.67
▼(-7.05% Downside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―